Weight loss therapy in obese hypertensive patients: the effect of orlistat versus metformin

Обертинська, О. Г.; Obertynska, O.

dc.contributor.author	Обертинська, О. Г.
dc.contributor.author	Obertynska, O.
dc.date.accessioned	2025-03-23T16:20:38Z
dc.date.available	2025-03-23T16:20:38Z
dc.date.issued	2021
dc.identifier.citation	Obertynska O. Weight loss therapy in obese hypertensive patients: the effect of orlistat versus metformin / O. Obertynska // EUROPEAN HEART JOURNAL. – 2021 – № 42(suppl. 1). – P. 2062	uk_UA
dc.identifier.issn	0195-668X
dc.identifier.uri	https://dspace.vnmu.edu.ua/123456789/8791
dc.description.abstract	29% of the obese hypertensive patients had >3 metabolic syndrome components. Abdominal obesity was the most common, followed by dyslipidemia, asymptomatic hyperuricemia and impaired glucose tolerance. Lifestyle program with diet alone wasn't enough for a reduction in weight and BP. Weight-loss program with orlistat is more effective than with metformin	uk_UA
dc.language.iso	en	uk_UA
dc.publisher	European Society of Cardiology	uk_UA
dc.subject	obesity	uk_UA
dc.subject	hypertension	uk_UA
dc.subject	treatment	uk_UA
dc.title	Weight loss therapy in obese hypertensive patients: the effect of orlistat versus metformin	uk_UA
dc.type	Thesis	uk_UA